查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1755939

2032 年感染疾病药物市场预测：按感染疾病类型、药物类别、给药方式、分销管道、最终用户和地区进行的全球分析

Infectious Disease Therapeutics Market Forecasts to 2032 - Global Analysis By Infection Type, Drug Class, Mode of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球感染疾病药物市场预计在 2025 年达到 1,352.5 亿美元，到 2032 年将达到 2,064.9 亿美元，预测期内的复合年增长率为 6.23%。

感染疾病药物涵盖多种旨在对抗细菌、病毒、真菌和寄生虫感染疾病的治疗方法。抗生素、抗病毒药物、抗真菌药物和抗寄生虫药物就是其中的一些例子，它们都作用于特定病原体，以根除感染或阻止其传播。随着抗药性细菌和感染疾病的增多，开发创新治疗方法和疫苗变得越来越重要。生物技术和分子诊断技术的发展使得更精准、更有效率的个人化治疗成为可能。

根据世界卫生组织 (WHO) 预测，到 2022 年，病毒性肝炎（乙型和丙型）将超过结核病，造成 130 万人死亡。预计到 2040 年，病毒性肝炎造成的死亡人数将超过疟疾、结核病和爱滋病造成的年度死亡人数总合，这凸显了对强效感染疾病物的迫切需求。

感染疾病率上升

感染疾病的流行仍然是全球最大的健康负担之一。根据世界卫生组织估计，爱滋病毒/爱滋病、肝炎、疟疾和结核病每年导致数百万人死亡，尤其是在中低收入国家。由于新冠肺炎 (COVID-19) 等疫情以及流感等季节性疾病的爆发，医疗保健系统也承受着巨大的压力。此外，这种持续且日益加重的负担迫切需要有效的治疗方法，以降低死亡率并改善患者预后。

昂贵的临床试验和药物开发

开发新型感染疾病治疗方法需要临床前研究、多个阶段的临床试验以及深入的研究和开发，所有这些都成本高且耗时。将一种药物推向市场可能需要十多年的时间，耗资数十亿美元。製药公司不愿开发主要影响低收入者的新型感染疾病治疗方法。此外，监管机构严格的安全性和有效性要求也推高了开发成本和时间。

增加生物防御和流行病防范支出

各国政府和国际组织正加大对卫生安全的投入，尤其註重开发应对新兴感染疾病威胁的快速反应平台、提升研发能力以及累积抗病毒药物。此外，世界卫生组织研发蓝图、美国生物医学高级机会与发展管理局（BARDA）和流行病防范创新联盟（CEPI）等计画也为药物研发人员提供了大量资金和合作机会。

病原体的快速进化和变异

细菌和病毒的适应性和快速突变有时会使现有疗法失效。 Omicron 等新型 COVID-19 变种的出现表明，病原体变异速度极快，甚至超过了疫苗和治疗方法的研发速度。此外，这种不可预测性也威胁长期治疗效果，需要持续监测、再投资和更新治疗通讯协定，这增加了製药公司的开发风险和成本。

COVID-19的影响：

新冠疫情改变了全球卫生优先事项，增加了资金投入，并加速了技术创新，所有这些都对感染疾病治疗市场产生了深远的影响。这导致了对mRNA技术、单株抗体和抗病毒药物的空前投资。监管机构采取了加速核准途径，为未来药物开发设立了新的标准，使得更快的治疗部署成为可能。疫情也增强了远端医疗和数位健康在疾病控制、促进跨境合作和提高公众感染疾病意识方面的作用。

疫苗领域预计将成为预测期内最大的领域

预计疫苗领域将在预测期内占据最大的市场占有率。全球意识的不断增强、政府对疫苗宣传活动的广泛支持以及免疫接种计划的广泛实施是疫苗占据主导地位的主要原因。如今，疫苗不仅提供预防性保护，也已成为控制流行病和流行疾病的策略工具。疫苗在成人和儿童族群中的广泛应用，加上mRNA和重组基因技术的不断发展，巩固了其市场领导地位，确保了其在已开发经济体和新兴经济体的稳定成长。

预计预测期内鼻腔部分将以最高的复合年增长率成长。

预计鼻腔给药领域将在预测期内达到最高成长率。这一增长可归因于对无针非侵入性给药技术日益增长的需求，这些技术可提高患者（尤其是年轻人和老年人）的依从性。此外，鼻腔给药製剂无需经胃肠道和首过代谢，起效迅速，使其成为紧急治疗和疫苗接种的理想选择。抗病毒喷剂和经鼻吸入型疫苗的最新进展提升了人们对该细分市场的兴趣和投资，使其成为未来成长的关键领域。

占比最大的地区：

预计北美将在预测期内占据最大的市场占有率。该地区拥有完善的医疗体系、高昂的医疗支出以及众多顶尖生物技术和製药公司的强劲发展势头。该地区拥有强大的研发能力、广泛的尖端治疗方法，以及令人欣喜的法规环境，例如快速的FDA核准流程。此外，肝炎、爱滋病毒和流感等感染疾病的高发病率、政府资助的疫苗接种和公共卫生宣传活动也对该地区市场占据主导地位宣传活动了重要作用。

复合年增长率最高的地区：

预计亚太地区在预测期内的复合年增长率最高。感染疾病率上升、医疗基础设施建设不断完善以及公共和私人部门对药物开发和医学研究的投资不断增加是推动这一增长的主要动力。在中国、印度和东南亚等国家，人口成长和疾病意识增强，推动了对更廉价、更有效治疗方法的需求。此外，该地区生物技术公司的推出、诊断技术的进步以及政府主导的疫苗接种宣传活动正在加速治疗方法的普及。该地区不断变化的法规环境也为快速扩张的市场提供了支持。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章全球感染疾病药物市场（依感染疾病类型）

  • 细菌感染疾病
  • 病毒感染
    • 人类免疫力缺乏病毒（HIV/AIDS）
    • B型肝炎
    • C型肝炎
    • 流感
    • HPV
  • 霉菌感染疾病
  • 寄生虫感染疾病
  • 其他类型的感染疾病

6. 全球感染疾病药物市场（依药物类别）

  • 抗菌剂
  • 抗病毒药物
  • 抗真菌药物
  • 抗寄生虫药
  • 疫苗
  • 其他药物类别

7. 全球感染疾病药物市场（依给药方式）

  • 口服
  • 肠外
  • 鼻内

第八章全球感染疾病药物市场按分销管道

  • 医院药房
  • 零售药局
  • 其他分销管道

第九章全球感染疾病药物市场（依最终用户）

  • 医院和诊所
  • 研究所
  • 诊断中心
  • 其他最终用户

第十章全球感染疾病药物市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • BioCryst Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim GmbH
  • Gilead Sciences Inc.
  • AstraZeneca Inc
  • Merck & Co., Inc.
  • Bayer AG
  • Amgen Inc.
  • Novartis AG
  • Bristol-Myers Squibb（BMS）
  • Abbott Laboratories
  • Pfizer Inc.
  • Sanofi
  • Janssen Pharmaceutical Inc.
  • Takeda Pharmaceutical
  • Sandoz International GmbH
Product Code: SMRC29833

According to Stratistics MRC, the Global Infectious Disease Therapeutics Market is accounted for $135.25 billion in 2025 and is expected to reach $206.49 billion by 2032 growing at a CAGR of 6.23% during the forecast period. Infectious disease therapeutics encompasses a broad range of treatments aimed at combating infections caused by bacteria, viruses, fungi, and parasites. Antibiotics, antivirals, antifungals, and antiparasitic medications are examples of these therapeutics; they all work against particular pathogens to eradicate or stop the spread of infection. The creation of innovative treatments and vaccines has become more and more important as drug-resistant bacteria and infectious diseases have increased. More accurate, efficient, and individualized treatments are now possible owing to developments in biotechnology and molecular diagnostics.

According to the World Health Organization, viral hepatitis (B and C) caused 1.3 million deaths in 2022, surpassing tuberculosis, and is projected to exceed the combined annual fatalities of malaria, TB, and AIDS by 2040-a stark indicator of the urgent need for potent infectious disease therapeutics.

Market Dynamics:

Driver:

Increasing infectious disease incidence

One of the biggest health burdens in the world is still the prevalence of infectious diseases. WHO estimates that HIV/AIDS, hepatitis, malaria, and tuberculosis together account for millions of deaths each year, particularly in low- and middle-income nations. Healthcare systems are also still under stress from outbreaks like COVID-19 and seasonal illnesses like influenza. Additionally, the need for efficient treatments to lower mortality and enhance patient outcomes is sustained by this ongoing and increasing burden.

Restraint:

Expensive clinical trials and drug development

Preclinical research, several stages of clinical trials, and intensive R&D are all necessary to develop new treatments for infectious diseases, and they are all costly and time-consuming. To get a single drug to market, it can take more than ten years and cost billions of dollars. Pharmaceutical companies are discouraged from pursuing new treatments for infectious diseases that primarily affect low-income populations because the return on investment may be low. Furthermore, raising development costs and timelines are regulatory bodies' strict safety and efficacy requirements.

Opportunity:

Increasing spending on biodefense and pandemic preparedness

Governments and international organizations are investing more in health security, with a particular emphasis on developing rapid-response platforms for emerging infectious threats, improving R&D capabilities, and accumulating antivirals. Moreover, drug developers can find substantial funding and collaboration opportunities through programs like WHO's R&D Blueprint, BARDA (Biomedical Advanced Research and Development Authority), and CEPI (Coalition for Epidemic Preparedness Innovations).

Threat:

Rapid pathogen evolution and mutation

Due to their high degree of adaptability and rapid mutation, bacteria and viruses can occasionally make current treatments ineffective. The appearance of novel COVID-19 variations, like Omicron, showed how quickly pathogens can change and surpass the development of vaccines and treatments. Additionally, long-term therapeutic efficacy is threatened by this unpredictability, necessitating ongoing monitoring, reinvestment, and treatment protocol updates, which raises development risks and costs for pharmaceutical companies.

Covid-19 Impact:

The COVID-19 pandemic changed the priorities of global health, boosted funding, and accelerated innovation, all of which had a substantial impact on the infectious disease therapeutics market. It highlighted the urgent need for quick therapeutic development, which resulted in previously unheard-of investments in mRNA technology, monoclonal antibodies, and antiviral medications. Faster treatment deployment was made possible by regulatory bodies' adoption of expedited approval pathways, which established a new standard for future drug development. The pandemic also increased the role of telemedicine and digital health in disease management, promoted cross-border cooperation, and raised public awareness of infectious diseases.

The vaccines segment is expected to be the largest during the forecast period

The vaccines segment is expected to account for the largest market share during the forecast period. Increased global awareness, extensive government support for vaccination campaigns, and extensive immunization programs are the main causes of this dominance. Vaccines are now a strategic tool for managing pandemics and epidemics in addition to providing preventive protection. Their widespread application in both adult and pediatric populations, combined with ongoing developments in mRNA and recombinant technologies, has strengthened their position as market leaders and guaranteed steady growth in both developed and emerging nations.

The intranasal segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the intranasal segment is predicted to witness the highest growth rate. This expansion is fueled by a growing desire, particularly among young and elderly populations, for needle-free, non-invasive drug delivery techniques that improve patient compliance. Moreover, intranasal formulations are perfect for emergency treatments and vaccinations because they provide a quick onset of action by avoiding the gastrointestinal tract and first-pass metabolism. Recent advancements in antiviral sprays and intranasal vaccines, increased interest in and investment in this market segment and established it as a crucial area for future growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, propelled by its sophisticated healthcare system, substantial healthcare expenditures, and robust presence of top biotechnology and pharmaceutical firms. The area gains from strong R&D capacities, broad use of cutting-edge treatment alternatives, and encouraging regulatory environments such as the FDA's expedited approval processes. Additionally, the high incidence of infectious diseases like hepatitis, HIV, and influenza, as well as government-sponsored immunization campaigns and public health campaigns, also play a big role in market dominance.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Rising infectious disease rates, growing healthcare infrastructure, and rising public and private investments in drug development and medical research are the main drivers of this growth. Because of their expanding populations and increased awareness of disease, countries like China, India, and Southeast Asia are seeking more affordable and efficient treatments. Furthermore, the launch of regional biotech companies, advancements in diagnostic technology and government-led vaccination campaigns are speeding up the adoption of treatments. The rapidly expanding market is further supported by the region's changing regulatory environment.

Key players in the market

Some of the key players in Infectious Disease Therapeutics Market include BioCryst Pharmaceuticals Inc. , GlaxoSmithKline plc, AbbVie Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Gilead Sciences Inc., AstraZeneca Inc, Merck & Co., Inc. , Bayer AG, Amgen Inc., Novartis AG, Bristol-Myers Squibb (BMS), Abbott Laboratories, Pfizer Inc. , Sanofi , Janssen Pharmaceutical Inc., Takeda Pharmaceutical and Sandoz International GmbH.

Key Developments:

In June 2025, BioCryst Pharmaceuticals, Inc. announced the extension of its consulting agreement with former Chief Financial Officer Anthony Doyle. This information was disclosed in a recent SEC filing. The company, with a market capitalization of $2.34 billion, has shown impressive momentum with a 66% return over the past year and revenue of $503 million in the last twelve months.

In February 2025, AbbVie and Xilio Therapeutics, Inc. announced collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology. Xilio has developed a proprietary, clinically-validated platform technology for tumor-activated biologics.

In January 2025, GSK plc has agreed to acquire IDRx, a Boston-based, clinical-stage Biopharmaceutical Company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.

Infection Types Covered:

  • Bacterial Infections
  • Viral Infections
  • Fungal Infections
  • Parasitic Infections
  • Other Infection Types

Drug Classes Covered:

  • Antibacterials
  • Antivirals
  • Antifungals
  • Antiparasitic Drugs
  • Vaccines
  • Other Drug Classes

Mode of Administrations Covered:

  • Oral
  • Parenteral
  • Intranasal

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

End Users Covered:

  • Hospitals & Clinics
  • Research Organizations
  • Diagnostic Centres
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Infectious Disease Therapeutics Market, By Infection Type

  • 5.1 Introduction
  • 5.2 Bacterial Infections
  • 5.3 Viral Infections
    • 5.3.1 Human Immunodeficiency Virus (HIV/AIDS)
    • 5.3.2 Hepatitis B
    • 5.3.3 Hepatitis C
    • 5.3.4 Influenza
    • 5.3.5 HPV
  • 5.4 Fungal Infections
  • 5.5 Parasitic Infections
  • 5.6 Other Infection Types

6 Global Infectious Disease Therapeutics Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Antibacterials
  • 6.3 Antivirals
  • 6.4 Antifungals
  • 6.5 Antiparasitic Drugs
  • 6.6 Vaccines
  • 6.7 Other Drug Classes

7 Global Infectious Disease Therapeutics Market, By Mode of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Intranasal

8 Global Infectious Disease Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Other Distribution Channels

9 Global Infectious Disease Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Research Organizations
  • 9.4 Diagnostic Centres
  • 9.5 Other End Users

10 Global Infectious Disease Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 BioCryst Pharmaceuticals Inc.
  • 12.2 GlaxoSmithKline plc
  • 12.3 AbbVie Inc.
  • 12.4 F. Hoffmann-La Roche Ltd.
  • 12.5 Boehringer Ingelheim GmbH
  • 12.6 Gilead Sciences Inc.
  • 12.7 AstraZeneca Inc
  • 12.8 Merck & Co., Inc.
  • 12.9 Bayer AG
  • 12.10 Amgen Inc.
  • 12.11 Novartis AG
  • 12.12 Bristol-Myers Squibb (BMS)
  • 12.13 Abbott Laboratories
  • 12.14 Pfizer Inc.
  • 12.15 Sanofi
  • 12.16 Janssen Pharmaceutical Inc.
  • 12.17 Takeda Pharmaceutical
  • 12.18 Sandoz International GmbH

List of Tables

  • Table 1 Global Infectious Disease Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Infectious Disease Therapeutics Market Outlook, By Infection Type (2024-2032) ($MN)
  • Table 3 Global Infectious Disease Therapeutics Market Outlook, By Bacterial Infections (2024-2032) ($MN)
  • Table 4 Global Infectious Disease Therapeutics Market Outlook, By Viral Infections (2024-2032) ($MN)
  • Table 5 Global Infectious Disease Therapeutics Market Outlook, By Human Immunodeficiency Virus (HIV/AIDS) (2024-2032) ($MN)
  • Table 6 Global Infectious Disease Therapeutics Market Outlook, By Hepatitis B (2024-2032) ($MN)
  • Table 7 Global Infectious Disease Therapeutics Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 8 Global Infectious Disease Therapeutics Market Outlook, By Influenza (2024-2032) ($MN)
  • Table 9 Global Infectious Disease Therapeutics Market Outlook, By HPV (2024-2032) ($MN)
  • Table 10 Global Infectious Disease Therapeutics Market Outlook, By Fungal Infections (2024-2032) ($MN)
  • Table 11 Global Infectious Disease Therapeutics Market Outlook, By Parasitic Infections (2024-2032) ($MN)
  • Table 12 Global Infectious Disease Therapeutics Market Outlook, By Other Infection Types (2024-2032) ($MN)
  • Table 13 Global Infectious Disease Therapeutics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 14 Global Infectious Disease Therapeutics Market Outlook, By Antibacterials (2024-2032) ($MN)
  • Table 15 Global Infectious Disease Therapeutics Market Outlook, By Antivirals (2024-2032) ($MN)
  • Table 16 Global Infectious Disease Therapeutics Market Outlook, By Antifungals (2024-2032) ($MN)
  • Table 17 Global Infectious Disease Therapeutics Market Outlook, By Antiparasitic Drugs (2024-2032) ($MN)
  • Table 18 Global Infectious Disease Therapeutics Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 19 Global Infectious Disease Therapeutics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 20 Global Infectious Disease Therapeutics Market Outlook, By Mode of Administration (2024-2032) ($MN)
  • Table 21 Global Infectious Disease Therapeutics Market Outlook, By Oral (2024-2032) ($MN)
  • Table 22 Global Infectious Disease Therapeutics Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 23 Global Infectious Disease Therapeutics Market Outlook, By Intranasal (2024-2032) ($MN)
  • Table 24 Global Infectious Disease Therapeutics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 25 Global Infectious Disease Therapeutics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 26 Global Infectious Disease Therapeutics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 27 Global Infectious Disease Therapeutics Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
  • Table 28 Global Infectious Disease Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global Infectious Disease Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 30 Global Infectious Disease Therapeutics Market Outlook, By Research Organizations (2024-2032) ($MN)
  • Table 31 Global Infectious Disease Therapeutics Market Outlook, By Diagnostic Centres (2024-2032) ($MN)
  • Table 32 Global Infectious Disease Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.